Henning Beltestad, CEO of Lerøy Seafood Group ASA (LSG), has today 11 November 2020 bought 18,000 shares in LSG at an average price of NOK 55.50 per share. Ownership after this transaction is 42,200 shares in LSG.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Black Friday researchers track the best Samsung TV deals for Black Friday, including offers on curved, frame, and flat models
The new mum admits the entire ordeal was 'terrifying' after having no pregnancy symptoms.
Malcolm Turnball says Morrison was 'dazzled and duchessed' by Trump on climate policyFormer PM says Scott Morrison needs to pivot his stance on foreign policy and climate change or risk Australia being seen as a ‘Trump-lite refuge’
Asian shares were mostly higher Tuesday, encouraged by news on the development of coronavirus vaccines and more assurance for a transition of power in the U.S. to President-elect Joe Biden. The U.S. federal government recognized Biden as the “apparent winner” of the Nov. 3 election, giving the green light for cooperation on a transition of power despite efforts by President Donald Trump to overturn the election. Hong Kong's Hang Seng inched up less than 0.1% to 26,500.81, while the Shanghai Composite slipped 0.5% to 3,398.47.
The latest Black Friday 4K TV deals for 2020, including all the best 50 inch, 55 inch, 60 inch, and larger HDR and 4K TV sales
(Bloomberg) -- Oil extended gains after closing at the highest level since August on signs Covid-19 vaccines could be rolled out within weeks and as the start of the U.S. presidential transition process aided markets in general.Futures in New York rose around 1% after settling above $43 a barrel on Monday. A vaccine developed by the University of Oxford and AstraZeneca Plc that prevented a majority of people from getting the disease could be deployed as soon as next month. That follows successful trials of two other anti-virus drugs. The triggering of a formal transition process to U.S. President-elect Joe Biden buoyed Asian stock markets and pushed down the dollar.See also: Covid Threatens Comeback After India’s Neighbors Beat First WaveVaccine optimism has oil heading for its best month since May, with investors looking past a worsening second wave that’s spurring more lockdown measures. Covid-19 is forecast to claim another 30,000 American lives by mid-December, Japan is moving toward boosting restrictions to contain the virus and Hong Kong is set to close bars and nightclubs, according to local media.The prospect of imminent drug rollouts is reshaping the oil futures curve. Global benchmark Brent’s prompt timespread flipped into backwardation -- a bullish structure where prompt contracts are more expensive than later-dated ones -- on Monday for the first time since June. A rebound in Chinese local flights is also aiding demand for jet fuel, the hardest-hit oil product.“The AstraZeneca vaccine is really a big deal as most developed markets will be able to immunize their most at-risk population to Covid-19 by spring,” said Stephen Innes, chief market strategist at Axi. “The continuing increase in infections in the U.S. and elsewhere has been the primary source of oil demand uncertainty.”The firming of the oil futures curve is a sign the market expects a rapid tightening of supplies ahead, RBC Capital Markets analysts wrote in a report. However, the forward curve for West Texas Intermediate looks overvalued with inventories still brimming at the Cushing, Oklahoma storage hub, they said.WTI’s discount to Brent widened to the most since May amid expectations for OPEC+ to extend current output cuts into next year. Some members of the group are showing signs of strain, however. Iraq is seeking upfront payments of about $2 billion in exchange for a long-term crude-supply contract, the latest sign of Baghdad’s growing desperation for cash.Saudi Arabia, meanwhile, confirmed that Houthi rebels in Yemen targeted an oil facility in northern Jeddah province, a reminder of the ever-present risk of instability in the region. The attack on Monday caused a fire at an oil tank inside a fuel-distribution center, the kingdom’s energy ministry said.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
In Pennsylvania, if you’re having friends over to socialize, you’re supposed to wear a mask — and so are your friends. In response, elected officials are imposing restrictions that, with some exceptions, fall short of the broad-based stay-at-home orders and business shutdowns seen in the spring.
The mining industry is making progress on the introduction of a zero carbon truck fleet by 2040, bringing in new partners as it strives to drive down emissions, the head of the International Council on Mining & Metals (ICMM) said on Tuesday. The initiative, announced two years ago, aims to minimise diesel exhaust and introduce vehicle collision avoidance technology by 2025, and hopes to see greenhouse gas emission-free surface mining vehicles used widely by 2040. The programme is backed by 27 of world's biggest miners including BHP Group and 18 original equipment manufacturers (OEMs), including Caterpillar, up from 11 OEMS two years ago, ICMM Chief Executive Tom Butler said.
Tuesday briefing: Joe Biden transition officially beginsGovernment departments told to open door for next presidency … half-dose may be the charm for Oxford vaccine … should we welcome back the wolves?
The lockdown view from York: ‘To be OK, we need to open on 3 December’Lockdown will end on 2 December – but there will still be strict regional restrictions. We look at how tourist businesses in York – which recorded the UK’s first Covid-19 cases – are adapting to the new normal
The award-winning author of Shuggie Bain speaks to Martin Chilton about the rejection-filled, 12-year journey to his debut novel and what it was like to grow up gay in a ‘hard man’s world’
Bonum Bank Plc will publish its financial statements (1 January 2020 – 31 December 2020) on 15 February 2021 by stock exchange release and on the website www.poppankki.fi. Also POP Bank Group will publish its financial statements bulletin (1 January 2020 – 31 December 2020) on 15 February 2021 on the website www.poppankki.fi. Bonum Bank Plc and POP Bank Group Further information: CEO Pekka Lemettinen, POP Bank Centre coop Tel. +358 40 5035 411, email: pekka.lemettinen@poppankki.fi CEO Pia Ali-Tolppa, Bonum Bank Plc Tel. +358 50 303 1476, email: pia.ali-tolppa@poppankki.fi Distribution: Nasdaq Helsinki Main media www.poppankki.fi The POP Bank Group is a Finnish financial group that offers retail banking services to private customers, small companies, agricultural and forestry companies, as well as non-life insurance services to private customers. 23 POP Bank serves nationwide with over 70 branch offices. According to independent EPSI Rating study of Finnish banks, POP Bank has the most satisfied private customers. Bonum Bank Plc, which is the central credit institution of POP Banks and a subsidiary of POP Bank Centre coop.
The Computer Aided Engineering (CAE) Market will grow by USD 4.27 bn during 2020-2024
Nilfisk, a leading provider of professional cleaning products and services, is announcing its results for the third quarter 2020. Highlights for Q3 2020 Demand continued to pick up month-over-month across all key markets during Q3 with some markets recording positive growth rates at the end of the quarterOverall demand is still at a lower level than usual due to negative impact from COVID-19 and its repercussions on macroeconomic conditions This led to organic growth of -7.3% for the total business, which posted revenue of 202.5 mEUR in Q3 2020. The branded professional business posted organic growth of ‑9.0%, supported by a positive monthly sequential development in EMEA and the USAcross regions, most customer segments showed positive signs of recovery except for the hospitality segment, which is hit hard by the pandemic. In the industrial segment, the macroeconomic repercussions of the pandemic had a negative impact on demandThe Consumer business had another strong quarter posting organic growth of 32.6% driven by continued high demand for high-pressure washers and a focused sales approach leading to new customer winsThe gross margin was 41.1%, which is in line with last year despite the negative impact of low capacity utilization at our production sites and higher logistics costs Overhead costs were reduced by 15.1 mEUR to 73.5 mEUR as a result of strict cost management and lower structural costs, improving the cost ratio by 2.6 percentage points compared to last year. The restructuring program announced in Q2 was largely completed during Q3 with close to 250 positions impactedDespite lower revenue, EBITDA before special items improved by 3.2 mEUR compared to last year and came to 25.5 mEUR corresponding to an EBITDA margin of 12.6%, which is 2.8 percentage points higher than last year Focus on working capital – in particular on inventory management and credit collection – continued in Q3. Compared to Q3 last year, working capital was reduced by 32.1 mEUR and the working capital ratio was 19.9% (20.1% in Q3 2019)Free cash flow in Q3 amounted to 5.6 mEUR driven by a positive operating result, balanced working capital development, a low level of special items, and a low CAPEX level Net interest-bearing debt was further reduced compared to end-Q2 and amounted to 402.3 mEUR (341.7 mEUR, excluding right-of-use liabilities), which is 29.3 mEUR lower than at the same time last year. The financial headroom, excluding right-of-use liabilities, to the total available credit facility was 208 mEUR Outlook for 2020 During the first part of Q4 we have seen a continued positive recovery trend in demand across all key markets, and, as a result, a continued positive development in our gross margin due to improved utilization of capacity. In addition, our continued efforts to tightly manage cost combined with a lower structural cost base have a positive impact on our operational leverage, positively impacting our earnings. However, we have also noted an escalation in the pandemic with renewed lock-down restrictions being introduced in many markets. While we have so far not experienced a material negative impact from this development, uncertainty remains at a higher level than usual. Based on this, we therefore maintain our current financial guidance but expect our full-year results for 2020 to materialize towards the top end of the range: Organic growth of -12% to -14%EBITDA margin before special items of 10.5% to 11.5% CEO comment Commenting on the results, Hans Henrik Lund, CEO of Nilfisk, says: “We are pleased to see an increase in market activity and demand throughout the quarter, following the heavy impact from the pandemic earlier in the year. We have been fully operational, and our sales representatives and service technicians have continued to support and service customers safely across markets. We saw many key markets return to positive growth rates in September.” “In parallel, we have continued the execution of our restructuring and have maintained tight cost management, and we have reduced overhead costs by more than 15 million euro compared to last year. These efforts led to improved earnings, both in nominal terms and in relative terms, and we are pleased with our results for Q3 2020”, says Hans Henrik Lund. Conference call Nilfisk will host a conference call today at 10:00 CET. Please visit investor.nilfisk.com to access the call. Presentation materials will be available on the website prior to the conference call. To dial in, please use the following numbers: Denmark: +45 8233 3194UK: +44 333 300 9268US: +1 833 823-0586 Link to webcast: https://streams.eventcdn.net/nilfisk/2020q3/ Contact Investor Relations Jens Bak-HolderHead of Investor Relations T: +45 2128 5832 Media Relations Steffen StoevelbaekGlobal Media RelationsT: +45 2067 0833 Attachments 12 Annoncement_24112020_Nilfisk Q3 Interim Report 2020 Nilfisk 2020-Q3 Interim Report
The Fuel Oil Utilities Market is poised to experience spend growth of more than USD 123 billion between 2020-2024 at a CAGR of over 3.85%.
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company. Close of business 23 Nov 2020. Estimated NAV Euro SharesSterling SharesEstimated NAV€ 25.1402£ 22.1534Estimated MTD return 4.18 % 3.82 %Estimated YTD return 9.79 % 7.35 %Estimated ITD return 151.40 % 121.53 % NAV and returns are calculated net of management and performance fees Market information Euro SharesAmsterdam (AEX)London (LSE)Market Close€ 19.00N/APremium/discount to estimated NAV -24.42 %N/A Sterling SharesAmsterdam (AEX)London (LSE)Market CloseN/AGBX 1,650.00Premium/discount to estimated NAVN/A -25.52 % Transactions in own securities purchased into treasury Ordinary Shares Euro SharesSterling SharesNumber of sharesN/AN/AAverage PriceN/AN/ARange of PriceN/AN/A Liquidity Enhancement AgreementEuro SharesSterling SharesNumber of sharesN/AN/AAverage PriceN/AN/A BGHL Capital BGHL Ordinary SharesEuro SharesSterling SharesShares Outstanding 13,772,778 301,536Held in treasury 189,000N/AShares Issued 13,961,778 301,536 Estimated BG Fund NAV Class B Euro Shares (estimated)€ 210.4453 The Class B Euro Shares of BG Fund are not subject to investment manager fees, as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL. For further information please contact: Boussard & Gavaudan Investment Management, LLP. Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.com The Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the "Shares") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities. This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute, or form part of, any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law. Neither the Company nor BG Fund ICAV has been, and neither will be, registered under the US Investment Company Act of 1940, as amended (the "Investment Company Act"). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"). Consequently any such securities may not be offered, sold or otherwise transferred within the United States or to, or for the account or benefit of, US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States. You should always bear in mind that: all investment is subject to risk; results in the past are no guarantee of future results; the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; and if you are in any doubt about the contents of this communication or if you consider making an investment decision, you are advised to seek expert financial advice. This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice. Attachment BGHL Publication 23.11
Montrouge, France, November 24, 2020 DBV Technologies Announces Leadership Changes DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Dr. Hugh Sampson has decided to step down from his role as Chief Scientific Officer (CSO) at DBV, effective December 1, 2020, to return to his research program at the Jaffe Food Allergy Institute at Mount Sinai. While acting as CSO, Dr. Sampson continued his commitment to the food allergy community by directing his research lab, running a NIH-sponsored prevention trial, and seeing patients in clinical practice part-time. Dr. Sampson will take on a new role as Scientific Adviser to the Chief Executive Officer and Chairman of DBV’s Scientific Advisory Board. In this capacity, he will remain involved in DBV’s ongoing development of epicutaneous immunotherapy (EPIT™). After three years serving on DBV’s Scientific Advisory Board, Dr. Sampson joined DBV in 2015 to formally lead the Company’s global scientific efforts and explore potential new applications of investigational Viaskin™ for the treatment of food allergies and autoimmune disorders, and for the development of novel vaccines. Dr. Sampson is the Kurt Hirschhorn Professor of Pediatrics at the Icahn School of Medicine at Mount Sinai and the Director Emeritus of the Jaffee Food Allergy Institute. He is a member of the National Academy of Medicine, past chair of the Section on Allergy & Immunology of the American Academy of Pediatrics and the past-president of the American Academy of Allergy, Asthma and Immunology. “Hugh is universally regarded as a leader in medical research in food allergy and immunology. We’re honored that he has contributed his remarkable expertise to advancing the Viaskin™ platform and shaping the scientific approach to our potential food allergy treatments. Today’s announcement is part of a thoughtful transition process, and we are grateful that he will continue to be an integral part of our team in his new role,” said Daniel Tassé, DBV’s Chief Executive Officer. “I’d like to thank Hugh for his commitment to our pursuit of improving patient outcomes and his ongoing, steadfast leadership.” “I have always been impressed by the dedication and energy of everyone at DBV, and it has been an honor for me to act as DBV’s Chief Scientific Officer for the past five years,” said Dr. Sampson. “I am proud of what DBV has accomplished in better understanding the biology of EPIT and its potential applications. Now is the right time for me to return to Mount Sinai and focus on my research programs in novel diagnostics and prevention of food allergy. We have worked with purpose to advance the potential behind the clinical profile of EPIT, and I am excited by the possibility that it may be a viable treatment option for millions of patients. I look forward to continuing to work with DBV to advance their efforts in my new capacity as Scientific Advisor to Daniel.” About DBV TechnologiesDBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT). Forward Looking StatementsThis press release may contain forward-looking statements and estimates, including statements regarding the potential benefits of Viaskin Peanut, the Company’s continued development of epicutaneous immunotherapy, and the Company’s transition plans. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, the Company’s products have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, including the impact of the COVID-19 pandemic. Furthermore, the timing of any action by any regulatory agency cannot be guaranteed. A further list and description of these risks, uncertainties and other risks can be found in the Company’s regulatory filings with the French Autorité des Marchés Financiers, the Company’s Securities and Exchange Commission filings and reports, including in the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and future filings and reports by the Company. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release. Investor Relations Contact Anne Pollak+ 1 (857) 529-2363anne.pollak@dbv-technologies.com Media ContactAngela Marcucci+1 (646) 842-2393angela.marcucci@dbv-technologies.com Attachment PDF Version
Klövern has signed a contract with Parfums Christian Dior for 973 sq.m. office space and a contract with Politiforbundet for 1,946 sq.m. office space in the so-called Codan-house on Gammel Kongevej in Copenhagen. Moving-in is estimated to be on 1 March 2021 and 1 June 2021, respectively. ”It is with great pleasure that we welcome our new tenants to the Codan-house where we have had a very great interest in rentals after our acquisition of the property. The Copenhagen rental market is strong and these lettings are steps in our plan to transform the property from a single-tenant property to an attractive modern multi-let property”, says Andreas Lange, Head of Klövern’s business unit Copenhagen. Klövern AB (publ) For additional information, please contact: Rutger Arnhult, CEO, +46 (0)70-458 24 70, rutger.arnhult@klovern.se Lars Norrby, IR, +46 (0)76-777 38 00, lars.norrby@klovern.se Klövern is a real estate company committed to working closely with customers to offer them attractive premises in growth regions. Klövern is listed on Nasdaq Stockholm. For further information, see www.klovern.se. Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Phone: +46 (0)10-482 70 00. E-mail: info@klovern.se. This is a translation of the original Swedish language press release. In the event of discrepancies, the original Swedish wording shall prevail. Attachment 201124 Klövern signs two new rental contracts in Copenhagen (pdf)
Award will help to fund planned Phase Ib/IIa study of inhaled murepavadin, a novel class antibiotic for the treatment of chronic Pseudomonas aeruginosa infections in cystic fibrosisDevelopment program is currently jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI) until end of planned Phase Ia study ALLSCHWIL, Switzerland, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Polyphor AG (SIX: POLN) today announced a funding agreement with the Cystic Fibrosis Foundation to advance clinical development of its novel class antibiotic, inhaled murepavadin, in cystic fibrosis (CF). Inhaled murepavadin is a highly potent and selective antibiotic against Pseudomonas aeruginosa, including multidrug resistant strains. CF is characterized by chronic bacterial infection and severe inflammation that lead to progressive deterioration in lung function. Under the terms of the agreement, Polyphor will be awarded up to USD $3.3 million to fund a Phase Ib/IIa clinical trial of inhaled murepavadin, as a follow-up study to a Phase Ia study in healthy volunteers using eFlow® Technology nebulizer (PARI Pharma GmbH), which is planned to be initiated pending CTA (clinical trial application) approval. The Phase Ib/IIa trial in adults with CF, assessing safety and tolerability (both overall and local) of ascending doses of inhaled murepavadin, is planned to be initiated in Q4 2021 following completion of the Phase Ia study. The Cystic Fibrosis Foundation Therapeutics Development Network (TDN) will provide support for the overall clinical development path for inhaled murepavadin. “Pseudomonas aeruginosa infection is a leading cause of lung function decline in people with cystic fibrosis and our novel class antibiotic, inhaled murepavadin, has the potential to change the treatment paradigm transforming patients’ lives,” said Gokhan Batur, Chief Executive Officer of Polyphor. “This is Polyphor’s second award from the Cystic Fibrosis Foundation, whose support had made possible nearly every cystic fibrosis-specific drug available today. The award will further encourage clinical development of inhaled murepavadin, and we would like to thank the Cystic Fibrosis Foundation for their trust and ongoing support.” About inhaled murepavadin: Polyphor’s inhaled murepavadin is currently being developed as a precision antibiotic specifically targeting chronic Pseudomonas aeruginosa, for the treatment of these infections in people with CF. It is the first member of the Outer Membrane Protein Targeting Antibiotics (OMPTA), a novel class of antibiotics which was discovered by Polyphor and the University of Zurich and displays a unique mode of action. Based on the data of the inhaled murepavadin preclinical program suggesting significantly higher safety margins (at least 5-10 times) versus the intravenous formulation, Polyphor is planning to initiate the clinical development program. Until the end of the planned Phase Ia study the program is jointly funded by Polyphor and the European Innovative Medicines Initiative (IMI). Inhaled murepavadin is also part of the iABC project, a Europe-wide program dedicated to the development of inhaled antibiotics run by a consortium of leading lung specialists and research institutions in various European countries. The Cystic Fibrosis Foundation award will allow further development until the end of the Phase Ib/IIa study. Infections remain a significant problem for people with CF who require novel treatment options, despite the availability of CFTR modulators. If approved for commercial use, inhaled murepavadin would be the first new class of antibiotics for Gram-negative pathogens in the last 50 years. It would also be potentially the first agent to target specifically Pseudomonas aeruginosa bacteria versus the current standard of care, broad spectrum inhaled antibiotics. For further information please contact: For Investors:Hernan LevettChief Financial OfficerPolyphor Ltd.+41 61 567 16 00IR@polyphor.comMary-Ann ChangLifeSci AdvisorsTel: +44 7483 284 853mchang@lifesciadvisors.com For Media: Bernhard SchmidLifeSci Advisors+41 44 447 12 21bschmid@lifesciadvisors.com About PolyphorPolyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance leveraging the company’s leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company’s lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com. DisclaimerThis press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor’s results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Not all products are born equal.
Yahoo Finance